LONDON, March 25, 2014 /PRNewswire/ --
The trading session on Monday, March 24,
2014 ended on a negative note as the Dow Jones Industrial
Average finished at 16,276.69, down 0.16% and the NASDAQ Composite
closed at 4,226.39, down 1.18%. The S&P 500 finished the
session 0.49% lower at 1,857.44. The losses were broad based as
eight out of ten sectors ended the session in negative. The S&P
500 Health Care Sector Index finished the day at 666.18, down 1.41%
and the same has fallen by 2.67% in the last one month.
Investor-Edge has initiated coverage on the following equities:
Quest Diagnostics Inc. (NYSE: DGX), Organovo Holdings Inc. (NYSE
MKT: ONVO), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher
Scientific Inc. (NYSE: TMO). Free technical research on DGX, ONVO,
A, and TMO can be downloaded upon signing up at:
http://www.investor-edge.com/447-register
On Monday, shares in Quest Diagnostics Inc. finished the session
0.45% lower at $55.52. The stock
recorded trading volume of 1.90 million shares as compared to a
three months average volume of 2.38 million shares. The stock
fluctuated between $55.22 and $55.90
during the session. Shares of the company traded at a PE ratio of
14.82. Quest Diagnostics Inc's stock has fallen by 0.52% in the
previous three trading sessions, while the same has gained 3.18% in
the last one month and 3.70% on YTD basis. The stock is trading
above its 50-day moving average. Quest Diagnostics Inc's 200-day
moving average of $58.03 is trading
above the 50-day moving average of $53.26. Moreover, the stock is trading at a
Relative Strength Index (RSI) of 68.88. Sign up today to read free
research on DGX at:
http://www.investor-edge.com/447-DGX-24Mar2014.pdf
Shares in Organovo Holdings Inc. reported a trading volume of 1.84
million shares, as compared with a three months average volume of
3.32 million shares. The stock ended the day at $8.38, down 0.83% and at an intraday range of
$8.01 and $8.38. Organovo Holdings Inc's shares have
declined 6.58% in the previous three trading sessions, 18.80% in
the last month, and 24.30% on YTD basis. The stock is trading above
its 200-day moving average. Organovo Holdings Inc's 50-day moving
average of $9.79 is trading above the
200-day moving average of $7.48.
Furthermore, the stock is trading at an RSI of 35.28. Sign up today
to read free research on ONVO at:
http://www.investor-edge.com/447-ONVO-24Mar2014.pdf
On Monday, shares in Agilent Technologies Inc. fell 1.48% to close
at $55.26. A total of 1.99 million
shares were traded, which is below the three months average volume
of 2.75 million. The stock oscillated between $54.66 and $56.23 during the trading session.
Shares of the company traded at a PE ratio of 21.92. Agilent
Technologies Inc's shares have fallen by 2.42% in the previous
three trading sessions, 2.63% in the last one month, and 3.37% on
YTD basis. The stock is trading above its 200-day moving average.
Agilent Technologies Inc's 50-day moving average of $57.90 is trading above the 200-day moving
average of $51.70. Furthermore, the
stock is trading at an RSI of 44.21. Sign up today to read free
research on A at:
http://www.investor-edge.com/447-A-24Mar2014.pdf
Shares in Thermo Fisher Scientific Inc. recorded a trading volume
of 2.76 million shares, as compared with a three months average
volume of 2.51 million shares. The stock ended the day at
$120.65, down 1.83% after vacillating
between $119.35 and $123.56. Shares of the company traded at a PE
ratio of 34.50. Thermo Fisher Scientific Inc's shares have fallen
by 1.69% in the previous three trading sessions and 2.20% in the
last one month, and have gained 8.35% on YTD basis. Further, the
company's stock is trading above its 50-day and 200-day moving
averages. Thermo Fisher Scientific Inc's 50-day moving average of
$119.64 is trading above the 200-day
moving average of $100.64.
Additionally, shares of the company are trading at an RSI of 50.95.
Sign up today to read free research on TMO at:
http://www.investor-edge.com/447-TMO-24Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://Investor-Edge.com
SOURCE Investor-Edge